These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 22090514

  • 1. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T.
    J Neurosci; 2011 Nov 16; 31(46):16884-94. PubMed ID: 22090514
    [Abstract] [Full Text] [Related]

  • 2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.
    Acta Neuropathol Commun; 2017 Feb 01; 5(1):11. PubMed ID: 28143577
    [Abstract] [Full Text] [Related]

  • 3. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H, Kato T, Arawaka S.
    Rev Neurosci; 2013 Feb 01; 24(2):115-23. PubMed ID: 23314528
    [Abstract] [Full Text] [Related]

  • 4. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.
    Nakamura Y, Arawaka S, Sato H, Sasaki A, Shigekiyo T, Takahata K, Tsunekawa H, Kato T.
    J Neurosci; 2021 Sep 01; 41(35):7479-7491. PubMed ID: 34290084
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates.
    Arawaka S, Sato H, Sasaki A, Koyama S, Kato T.
    Acta Neuropathol Commun; 2017 Jun 15; 5(1):48. PubMed ID: 28619113
    [Abstract] [Full Text] [Related]

  • 6. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, Vollenweider I, Baud L, Piron C, Grouthier V, Boraud T, Porras G, Li Q, Baekelandt V, Scheller D, Michel A, Fernagut PO, Georges F, Courtine G, Bezard E, Dehay B.
    Acta Neuropathol Commun; 2015 Jul 25; 3():46. PubMed ID: 26205255
    [Abstract] [Full Text] [Related]

  • 7. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
    Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D.
    Neurobiol Dis; 2015 Jun 25; 78():100-14. PubMed ID: 25818009
    [Abstract] [Full Text] [Related]

  • 8. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.
    Neurobiol Dis; 2008 Apr 25; 30(1):8-18. PubMed ID: 18313315
    [Abstract] [Full Text] [Related]

  • 9. Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.
    Taschenberger G, Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, Kügler S.
    Acta Neuropathol; 2012 May 25; 123(5):671-83. PubMed ID: 22167382
    [Abstract] [Full Text] [Related]

  • 10. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
    Waxman EA, Giasson BI.
    J Neuropathol Exp Neurol; 2008 May 25; 67(5):402-16. PubMed ID: 18451726
    [Abstract] [Full Text] [Related]

  • 11. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
    Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM.
    PLoS One; 2011 Mar 07; 6(3):e17698. PubMed ID: 21408191
    [Abstract] [Full Text] [Related]

  • 12. In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain.
    Bergeron M, Motter R, Tanaka P, Fauss D, Babcock M, Chiou SS, Nelson S, San Pablo F, Anderson JP.
    Neuroscience; 2014 Jan 03; 256():72-82. PubMed ID: 24128992
    [Abstract] [Full Text] [Related]

  • 13. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S, García-Yagüe ÁJ, López-Royo T, Casarejos M, Lanciego JL, Lastres-Becker I.
    Glia; 2018 Aug 03; 66(8):1752-1762. PubMed ID: 29624735
    [Abstract] [Full Text] [Related]

  • 14. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
    Alerte TN, Akinfolarin AA, Friedrich EE, Mader SA, Hong CS, Perez RG.
    Neurosci Lett; 2008 Apr 11; 435(1):24-9. PubMed ID: 18314273
    [Abstract] [Full Text] [Related]

  • 15. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
    Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, Muzyczka N.
    Proc Natl Acad Sci U S A; 2008 Jan 15; 105(2):763-8. PubMed ID: 18178617
    [Abstract] [Full Text] [Related]

  • 16. S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson's disease.
    Wu W, Sung CC, Yu P, Li J, Chung KKK.
    PLoS One; 2020 Jan 15; 15(4):e0232019. PubMed ID: 32343709
    [Abstract] [Full Text] [Related]

  • 17. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.
    J Neurosci; 2002 Apr 01; 22(7):2780-91. PubMed ID: 11923443
    [Abstract] [Full Text] [Related]

  • 18. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP, Schonhoff AM, Jurkuvenaite A, Thome AD, Standaert DG, Harms AS.
    J Neuroinflammation; 2018 Aug 30; 15(1):244. PubMed ID: 30165873
    [Abstract] [Full Text] [Related]

  • 19. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S, Fukushima S, Sato H, Sasaki A, Koga K, Koyama S, Kato T.
    PLoS One; 2014 Aug 30; 9(2):e89076. PubMed ID: 24586512
    [Abstract] [Full Text] [Related]

  • 20. Serine 129 phosphorylation of membrane-associated α-synuclein modulates dopamine transporter function in a G protein-coupled receptor kinase-dependent manner.
    Hara S, Arawaka S, Sato H, Machiya Y, Cui C, Sasaki A, Koyama S, Kato T.
    Mol Biol Cell; 2013 Jun 30; 24(11):1649-60, S1-3. PubMed ID: 23576548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.